Skip to main content
ADPT
NASDAQ Life Sciences

NCCN Guidelines Now Specifically Name clonoSEQ, Prefer 10^-6 MRD Sensitivity in Myeloma

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$27.98
Mkt Cap
$4.416B
52W Low
$12
52W High
$28.72
52W Position info
133% above low
Off High info
2.6% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

ADPT has more than doubled off its 52-week low of $12 on elevated volume (1.8× avg).

Summary

The NCCN Clinical Practice Guidelines for Multiple Myeloma now include a dedicated MRD testing page (MYEL-E) and specifically name clonoSEQ as the only FDA-cleared assay for MRD assessment. The guidelines state 10^-6 sensitivity is preferred, with 10^-5 as minimum, and expand recommended testing timepoints to include annual maintenance and post-CAR T-cell therapy. This is a meaningful regulatory/clinical endorsement that could accelerate clonoSEQ adoption in community oncology practices, where NCCN guidelines heavily influence treatment decisions. The update follows Adaptive's strong Q2 results and raised MRD revenue guidance, reinforcing the company's commercial momentum. Watch for any commentary from management on expected revenue impact from this guideline change.

At the time of this announcement, ADPT was trading at $27.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $12.00 to $28.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Nov 04, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.48
Real-time Price: $28.10 info
Change: -$0.380 (-1%) info
Market Cap: $4.549B info
ADPT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $28.10 info
Change: -$0.6999 (-2%) info
Market Cap: $4.549B info
ADPT
Aug 19, 2026, 8:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $28.10 info
Change: +$2.30 (+9%) info
Market Cap: $4.549B info
ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $28.10 info
Change: +$3.44 (+14%) info
Market Cap: $4.549B info
ADPT
Jul 29, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.15
Real-time Price: $28.10 info
Change: +$5.95 (+27%) info
Market Cap: $4.549B info